NASDAQ:CLXT Calyxt (CLXT) Stock Price, News & Analysis → Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad) Free CLXT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.01▼$7.7750-Day Range$6.30▼$31.5052-Week Range$1.25▼$7.77Volume254,056 shsAverage Volume139,308 shsMarket Capitalization$31.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Calyxt alerts: Email Address Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Calyxt Stock (NASDAQ:CLXT)Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company to enhance the quality of alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota.Read More Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. CLXT Stock News HeadlinesMay 20, 2023 | seekingalpha.comCalyxt stockholders approve merger and reverse stock split; anticipated name change and ticker symbol for combined companyMay 19, 2023 | finance.yahoo.comCalyxt Announces Stockholder Approval of Merger With CibusApril 29, 2024 | Huge Alerts (Ad)The #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!May 1, 2023 | finance.yahoo.comCalyxt Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 24, 2023 | finance.yahoo.comCalyxt Completes One-for-Ten Reverse Stock SplitApril 18, 2023 | finance.yahoo.comCalyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLCApril 13, 2023 | finanznachrichten.deCalyxt, Inc.: Calyxt Announces Effective Date of Reverse Stock SplitApril 7, 2023 | finance.yahoo.comCalyxt Announces Effective Date of Reverse Stock SplitApril 29, 2024 | Huge Alerts (Ad)The #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!March 9, 2023 | prnewswire.comCALYXT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Calyxt, Inc. - CLXTMarch 6, 2023 | finance.yahoo.comCalyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate UpdateMarch 2, 2023 | finance.yahoo.comCalyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate UpdateFebruary 21, 2023 | sg.finance.yahoo.comCalyxt, Inc. (CLXT) stock historical prices & data – Yahoo FinanceFebruary 15, 2023 | finance.yahoo.comCalyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLCJanuary 18, 2023 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Calyxt, Inc. has entered into a Fair Transaction with CibusJanuary 17, 2023 | prnewswire.comSHAREHOLDER ALERT: Weiss Law Investigates Calyxt, Inc.January 17, 2023 | finance.yahoo.comCalyxt Shares Surge On Merger Agreement Creating Agriculture-Focused Precision Gene Editing CompanyJanuary 17, 2023 | investorplace.comWhy Is Calyxt (CLXT) Stock Up 140% Today?December 20, 2022 | finance.yahoo.comCalyxt, Inc. (CLXT) Stock Historical Prices & Data - Yahoo FinanceNovember 20, 2022 | fool.comCalyxt, Inc. (NASDAQ: CLXT)November 18, 2022 | finance.yahoo.comCalyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm OilNovember 17, 2022 | finance.yahoo.comCalyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price RuleNovember 9, 2022 | finance.yahoo.comCalyxt Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 3, 2022 | finance.yahoo.comCalyxt Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 3, 2022 | finance.yahoo.comCalyxt (CLXT) Reports Q3 Loss, Misses Revenue EstimatesNovember 1, 2022 | finance.yahoo.comCalyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based BiomanufacturingOctober 27, 2022 | finance.yahoo.comCalyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern TimeSee More Headlines Receive CLXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calyxt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2023Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CLXT CUSIPN/A CIK1705843 Webwww.calyxt.com Phone(651) 683-2807FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,890,000.00 Net Margins-9,979.64% Pretax Margin-9,979.64% Return on Equity-259.69% Return on Assets-83.22% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual Sales$160,000.00 Price / Sales195.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book11.67Miscellaneous Outstanding Shares4,970,000Free Float4,865,000Market Cap$31.31 million OptionableNot Optionable Beta1.98 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Michael Allen Carr (Age 53)Pres, CEO & Director Comp: $543.56kMr. William F. Koschak (Age 54)Chief Financial Officer Comp: $356.74kDr. Travis J. Frey Ph.D. (Age 44)Chief Technology Officer Comp: $314.76kMs. Debra H. Frimerman (Age 43)Gen. Counsel & Corp. Sec. Comp: $334.08kDr. Daniel F. Voytas Ph.D. (Age 60)Founder, Chief Science Officer & Chair of Scientific Advisory Board Dr. Stephen M. BravoChief Medical OfficerMr. Gerry NuovoSr. VP of Bus. Devel.More ExecutivesKey CompetitorsLianBioNASDAQ:LIANTevogen BioNASDAQ:TVGNChina Green AgricultureNYSE:CGAPHAXIAM TherapeuticsNASDAQ:PHXMKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInsidersRory B RiggsBought 200 shares on 6/1/2023Total: $31,500.00 ($157.50/share) CLXT Stock Analysis - Frequently Asked Questions How were Calyxt's earnings last quarter? Calyxt, Inc. (NASDAQ:CLXT) announced its quarterly earnings results on Monday, May, 1st. The company reported ($5.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.00) by $2.45. The company had revenue of $0.04 million for the quarter. Calyxt had a negative net margin of 9,979.64% and a negative trailing twelve-month return on equity of 259.69%. When did Calyxt's stock split? Calyxt shares reverse split on the morning of Thursday, June 1st 2023. The 1-5 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Calyxt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calyxt investors own include Cellectis (CLLS), Molecular Templates (MTEM), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Cypress Semiconductor (CY), Dynavax Technologies (DVAX), GW Pharmaceuticals (GWPH), Iovance Biotherapeutics (IOVA) and Invitae (NVTA). When did Calyxt IPO? Calyxt (CLXT) raised $101 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,100,000 shares at a price of $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers. This page (NASDAQ:CLXT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsMan Who Predicted 2008: “This Will be Worse.”AltimetryWhy Big Pharma is Investing Billions in This BiotechBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calyxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
